Recent Updates
Recently added Catalysts
IVVD Negative Sentiment Score: 20/100

INVIVYD SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI

Key Takeaway: Kahn Swick & Foti, LLC is reminding investors of a class action lawsuit against Invivyd, Inc. (formerly Adagio Therapeutics) due to material nondisclosures during its Class Period from November 29 to December 14, 2021. The lawsuit follows a significant decline in share price following revelations regarding the ineffectiveness of the company's COVID-19 product against the Omicron variant. Investors with losses over $100,000 are encouraged to submit lead plaintiff applications by April 3, 2023, to protect their rights in the case. This legal action highlights concerns about transparency and investor trust regarding Invivyd's disclosures.

Market Sentiment Analysis

CONCERNS & RISKS

  • Invivyd is facing a securities class action lawsuit due to undisclosed material information.
  • The company's shares plummeted nearly 80% after disclosing concerning test results for its COVID-19 product.
  • The lawsuit involves potential recovery for investors who suffered significant losses.

Full Press Release Details

NEW ORLEANS, March 07, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (“Adagio”) (NasdaqGM: ADGI), if they purchased the Company’s shares between November 29, 2021 and December 14, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
If you purchased shares of Invivyd and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-ivvd/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 3, 2023.
Invivyd and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 14, 2021, the Company (then named Adagio) disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.
On this news, shares of Adagio plummeted nearly 80%, from $34.26 per share on December 13, 2021, to $7.26 per share when the market closed on December 14, 2021.
The case is Brill v. Invivyd, Inc., No. 23-cv-10254.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

Lead plaintiff applications must be filed by April 3, 2023.

Who should contact KSF regarding the lawsuit?

Investors who purchased Invivyd shares during the Class Period should contact KSF.

Why are Invivyd executives facing legal action?

They are accused of failing to disclose material information, violating securities laws.

What caused the drop in Adagio's share price?

The share price fell after it was revealed that ADG20 was less effective against Omicron.

What is the case name and number against Invivyd?

The case is Brill v. Invivyd, Inc., No. 23-cv-10254.

Last updated: Mar 8, 2023